Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Growth in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,720,000 shares, an increase of 13.2% from the December 15th total of 1,520,000 shares. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 5.2% of the company’s shares are short sold.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. PFM Health Sciences LP increased its stake in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after purchasing an additional 157,673 shares during the period. Millennium Management LLC raised its holdings in Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after purchasing an additional 544,881 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Werewolf Therapeutics by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after buying an additional 40,692 shares in the last quarter. State Street Corp lifted its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after purchasing an additional 52,528 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities dropped their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th.

Werewolf Therapeutics Stock Down 0.7 %

Shares of HOWL opened at $1.33 on Monday. The company’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $2.09. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market capitalization of $59.26 million, a PE ratio of -0.87 and a beta of 0.38. Werewolf Therapeutics has a 1 year low of $1.31 and a 1 year high of $8.19.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.